索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]伍思颖,伍伟锋.成人房间隔缺损合并肺动脉高压的缺损闭合治疗[J].国际心血管病杂志,2021,02:91-93.
点击复制

成人房间隔缺损合并肺动脉高压的缺损闭合治疗(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2021年02期
页码:
91-93
栏目:
综述
出版日期:
2021-03-20

文章信息/Info

Title:
-
作者:
伍思颖; 伍伟锋
530021 南宁,广西医科大学第一附属医院心血管内科
Author(s):
-
关键词:
房间隔缺损;  肺动脉高压;  封堵术
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2021.02.007
文献标识码:
-
摘要:
随着成人先天性心脏病临床处理指南的更新,成人房间隔缺损合(ASD)合并肺动脉高压(PH)的缺损闭合治疗策略有了新进展。该文简述成人ASD合并PH的临床分类及特点,重点介绍ASD合并PH的缺损闭合策略,包括常规缺损闭合、“药物到缺损闭合”策略以及带孔封堵器封堵术等。
Abstract:
-

参考文献/References

[1] Engelfriet PM, Duffels MG, Möller T, et al. Pulmonary arterial hypertension in adults born with a heart septal defect: the Euro Heart Survey on adult congenital heart disease[J]. Heart, 2007, 93(6):682-687.
[2] Zwijnenburg RD, Baggen VJM, Geenen LW, et al. The prevalence of pulmonary arterial hypertension before and after atrial septal defect closure at adult age: a systematic review[J]. Am Heart J, 2018, 201:63-71.
[3] Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology(ESC)and the European Respiratory Society(ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology(AEPC), International Society for Heart and Lung Transplantation(ISHLT)[J]. Eur Heart J, 2016, 37(1):67-119.
[4] Stout KK, Daniels CJ, Aboulhosn JA, et al. 2018 AHA/ACC guideline for the management of adults with congenital heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines[J]. Circulation, 2019, 139(14):e831-e832.
[5] Baumgartner H, De Backer J, Babu-Narayan SV, et al. 2020 ESC Guidelines for the management of adult congenital heart disease[J]. Eur Heart J, 2020:ehaa554.
[6] Aminde LN, Dzudie A, Takah NF, et al. Current diagnostic and treatment strategies for Lutembacher syndrome: the pivotal role of echocardiography[J]. Cardiovasc Diagn Ther, 2015, 5(2):122-132.
[7] Vasan RS, Shrivastava S, Kumar MV. Value and limitations of Doppler echocardiographic determination of mitral valve area in Lutembacher syndrome[J]. J Am Coll Cardiol, 1992, 20(6):1362-1370.
[8] Webb G, Gatzoulis MA. Atrial septal defects in the adult: recent progress and overview[J]. Circulation, 2006, 114(15):1645-1653.
[9] Balint OH, Samman A, Haberer K, et al. Outcomes in patients with pulmonary hypertension undergoing percutaneous atrial septal defect closure[J]. Heart, 2008,94(9):1189-1193.
[10] Yong G, Khairy P, De Guise P, et al. Pulmonary arterial hypertension in patients with transcatheter closure of secundum atrial septal defects: a longitudinal study[J]. Circ Cardiovasc Interv, 2009, 2(5):455-462.
[11] Manes A, Palazzini M, Leci E, et al. Current era survival of patients with pulmonary arterial hypertension associated with congenital heart disease: a comparison between clinical subgroups[J]. Eur Heart J, 2014, 35(11): 716-724.
[12] van Albada ME, Berger RM. Pulmonary arterial hypertension in congenital cardiac disease—the need for refinement of the Evian-Venice classification[J]. Cardiol Young, 2008, 18(1):10-17.
[13] Rondelet B, Kerbaul F, Motte S, et al. Bosentan for the prevention of overcirculation-induced experimental pulmonary arterial hypertension[J]. Circulation, 2003, 107(9):1329-1335.
[14] Theo Schermuly R, Ardeschir Ghofrani H, Weissmann N. Prostanoids and phosphodiesterase inhibitors in experimental pulmonary hypertension[J]. Curr Top Dev Biol, 2005, 67:251-284.
[15] Bradley EA, Chakinala M, Billadello JJ. Usefulness of medical therapy for pulmonary hypertension and delayed atrial septal defect closure[J]. Am J Cardiol, 2013, 112(9):1471-1476.
[16] Kijima Y, Akagi T, Takaya Y, et al. Treat and repair strategy in patients with atrial septal defect and significant pulmonary arterial hypertension[J]. Circ J, 2016, 80(1):227-234.
[17] Bradley EA, Ammash N, Martinez SC, et al. "Treat-to-close": non-repairable ASD-PAH in the adult: results from the North American ASD-PAH(NAAP)Multicenter Registry[J]. Int J Cardiol, 2019, 291:127-133.
[18] Arvind B, Relan J, Kothari SS. "Treat and repair" strategy for shunt lesions: a critical review[J]. Pulm Circ, 2020, 10(2):2045894020917885.
[19] Holzer R, Cao QL, Hijazi ZM. Closure of a moderately large atrial septal defect with a self-fabricated fenestrated Amplatzer septal occluder in an 85-year-old patient with reduced diastolic elasticity of the left ventricle[J]. Catheter Cardiovasc Interv, 2005, 64(4):513-518.
[20] Humenberger M, Rosenhek R, Gabriel H, et al. Benefit of atrial septal defect closure in adults: impact of age[J]. Eur Heart J, 2011, 32(5):553-560.
[21] Bruch L, Winkelmann A, Sonntag S, et al. Fenestrated occluders for treatment of ASD in elderly patients with pulmonary hypertension and/or right heart failure[J]. J Interv Cardiol, 2008, 21(1):44-49.
[22] Dalvi B, Jain S, Pinto R. Device closure of atrial septal defect with severe pulmonary hypertension in adults: Patient selection with early and intermediate term results[J]. Catheter Cardiovasc Interv, 2019, 93(2):309-315.

备注/Memo

备注/Memo:
通信作者:伍伟锋,E-mail:wucna65@163.com
更新日期/Last Update: 2021-03-20